Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company's cell-gene-immunotherapy for pancreatic cancer and, potentially, other solid tumors, as well as the accelerated timeline for submission of the company's Pre-Investigational New Drug ("Pre-IND") application to the U.S. FDA. "Despite significant challenges that would have derailed many companies, our strategic plan to focus on our most promising platform has allowed us to significantly de-risk our cancer immune oncology program and be in a strong position now. We have made substantial scientific and product development advances over the past 10 months. This was accomplished while substantially reducing operating costs – including, at my request, a decrease in my compensation as CEO - towards maximizing shareholder value," Dr. Dybul wrote in the letter. "The progress with a platform that has key attributes that could potentially be leveraged for products to treat solid tumors, HIV and, perhaps, other infectious diseases is particularly encouraging."

To view the full press release, visit https://ibn.fm/rDFuI

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.

RENB-DC11

Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

• RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
• RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
• RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
• RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
  LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Friday's trading session at $1.67, up 3.0864%, on 142,082 volume. The average volume for the last 3 months is 12,222 and the stock's 52-week low/high is $0.3928/$2.74.

Recent News

• Renovaro BioSciences Inc. (NASDAQ: RENB) - InvestorNewsBreaks - Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders
• InvestorNewsBreaks - Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of 'Impressive' Results from Proof-of-Concept Studies
• InvestorNewsBreaks - Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs

BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature

Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development

The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23%

Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies ("mAbs") and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two - one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.

Autoimmune diseases occur when the immune system mistakes healthy tissues for harmful bacteria, viruses, or infections and starts to attack the body. Referred to as autoimmunity, this phenomenon causes significant damage to healthy tissues and results in more than 100 autoimmune conditions. Data has consistently shown that women are four times more likely to develop autoimmune diseases compared to men. While some researchers have posited that the X chromosome may increase the risk of autoimmunity in women because it is more likely to cause a higher number of mutations, we still don't know why autoimmune diseases affect women at much higher rates. Still, gender plays a significant role in immunity, and the fact that women deal with autoimmunity in higher rates means that gender likely plays a role in the development of autoimmune conditions. In that vein, the hormonal contraceptives used by millions of women across America may play a role in increasing autoimmunity risk. Given that contraception is needed for a variety of reasons, efforts by companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to leverage immunotherapy in an effort to address autoimmunity can come in handy for women who develop autoimmune conditions as a result of their use of hormonal contraceptives.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $1.35, up 3.0534%, on 12,222 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.74/$.

Recent News

• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) - Analyzing Link Between Hormonal Contraceptives, Autoimmunity
• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
• InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

In an unprecedented move, New York made history by making marijuana legally available for purchase at a special farmers' market for adults only in Ulster County. The main goal of this creative move was to address the oversupply situation that many marijuana growers are currently in. While stringent security measures ensured that only those with verified IDs could enter the farmer-market space, the scene within the event resembled that of a conventional farmers' market, complete with sprawling tents, neatly arranged tables, inquisitive consumers and well-informed farmers. The event, held in New Paltz, was New York's first attempt at staging a pop-up market solely for cannabis. Despite the continuous rain, eager consumers formed queues as four cannabis farms prepared to engrave their names in history. If the pop-markets serve their stop-gap role of helping growers sell the bulk of their stockpiled marijuana, other cultivation companies may also enjoy the impetus they need to get modern cultivation equipment from various manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX) to scale up their operations as more retailers are licensed by the state.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.21, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0141/$0.65.

Recent News

• Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - New Paltz, NY Farmers' Market Draws Marijuana Enthusiasts
• 420 with CNW - Three States in the Northeast Set July Cannabis Sales Records
• 420 with CNW - Court Order Halts NY Marijuana Dispensary Openings

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network (OTCQB: XESP) developed its Digital Engagement Engine(TM) technology to disrupt the market by helping clients maintain control of their content while dynamically engaging their audiences. "The Digital Engagement Engine(TM) makes content marketing and, by extension, conversational marketing exponentially effective. The tech stack can identify the narrowest of niches within a target market and target leads with great accuracy. It tailors content to address audience members' precise interests and needs and dynamically delivers it to them right when they need it," a recent article reads. "The Digital Engagement Engine overlays with the [conversational marketing and omnichannel content publication] tools to ensure that you are having a co-created conversation that is meaningful to the individual user rather than a one-size-fits-all," XESP CEO Peter Hager is quoted as saying. "That meaningful interaction drives a greater relationship with your audience and trust. Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face. And if we can do that online, which the Digital Engagement Engine helps you do, you're going to produce better results."

To view the full article, visit https://ibn.fm/XXq2k

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.

Technology

Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by ReportLinker.com, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Friday's trading session at $0.06, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.201.

Recent News

• Electronic Servitor Publication Network Inc. (OTCQB: XESP) - TechMediaBreaks - Electronic Servitor Publication Network Inc.'s (XESP) Digital Engagement Engine(TM) Helps Brands Drive Growth
• TechMediaBreaks - Electronic Servitor Publication Network Inc.'s (XESP) 'Growth-as-a-Service' Platform Helping Companies Enhance User Engagement
• Electronic Servitor Publication Network Inc. (XESP) Taps into Growth in Conversational Commerce Market

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

FEXD is developing a global financial technology ecosystem that will address unmet mobile money needs in developing and industrialized markets and make it easier and more affordable to transact digitally

The company aims to use emerging technologies such as AI to reduce costs associated with and fast-track the processing of money transfers and loans

AI is a powerful technology that has been positively associated with the improvement in digital financial inclusion

The technology is used in credit risk assessment, investment-related decision-making, fraud detection and prevention, prediction, and customer service

With FEXD eying digital money transfers, which are unfortunately prone to cyber threats and fraud attempts, the company aims to tap into the power of AI to promote security and efficiency, thus driving digital financial inclusion

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a company working to develop a global financial technology ecosystem comprising a network of mobile money platforms, technologies, applications, products, and services. "The technologies, the company's website states, are meant to ‘make it easy to move money across borders to almost any place in the world, in virtually any currency, using your mobile phone or laptop.' FEXD aims to use emerging technologies such as blockchain, web 3.0, artificial intelligence ("AI"), and the metaverse to reduce costs and accelerate the processing of money transfers, loans and other lifestyle services, which will benefit consumers and businesses in many countries, according to Dr. Sainful Khandaker, CEO, president and founder of FEXD," a recent article reads. "With a goal of leveraging the power of such emerging technologies to benefit businesses and consumers downstream, FEXD is not only developing platforms and applications that support cashless transactions but also seeking to acquire and merge with high-growth global fintech companies primarily operating in South Asia with a high volume of customers and extensive network of agents."

To view the full article, visit https://ibn.fm/XQZqy

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Friday's trading session at $10.59, off by 1.1223%, on 513 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.03/$11.00.

Recent News

• Fintech Ecosystem Development Corp. (NASDAQ: FEXD) - Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Driving Digital Financial Inclusion on Power and Capabilities of Artificial Intelligence
• InvestorNewsBreaks - Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Eyes Leveraging Emerging Technologies to Reduce Costs, Accelerate Processing of Money Transfers
• InvestorNewsBreaks - Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Pushing AI Conversation Forward

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots ("ASRs") and blue light emergency communication systems, has announced a new contract with a self-storage company for an initial order of five K5 ASRs. According to the update, the client is one of the fastest-growing self-storage platforms in the United States with assets located primarily in high-density, urban markets.

The announcement reads, "Knightscope's K5 ASRs will patrol five storage locations – two in the Portland area and three others in California – to help mitigate risk and elevate the protection offered to tenants and their belongings. In addition to their security duties, the robots will broadcast helpful messages to passersby and act as brand ambassadors. Based on the success of these initial deployments, the client will be considering deployments at many other store locations."

To view the full press release, visit https://ibn.fm/K4OoD

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

• Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
• Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
• Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Friday's trading session at $1.26, off by 2.3256%, on 1,068,046 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.36/$3.65.

Recent News

• Knightscope (NASDAQ: KSCP) - InvestorNewsBreaks - Knightscope, Inc. (NASDAQ: KSCP) K5 ASRs to Deploy with Major Self-Storage Platform
• Knightscope Inks Deal with Major Player in Self Storage
• InvestorNewsBreaks - Knightscope, Inc. (NASDAQ: KSCP) Provides Q2 Update Video, Announces New ASR Deployment, Adds Roadshow Date to Calendar

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today announced that its 2023 Mullen "Strikingly Different" EV Tour kicks off this weekend, Aug 20-21, at Circuit of the Americas in Austin, Texas. The tour is slated to run until Nov. 15, 2023, covering the South, East Coast, Midwest, and West Coast before finishing up in California. During the 2023 tour, the public will have the opportunity to see, test drive and experience Mullen's commercial and retail EVs and check out the latest electric vehicle technology the company has been working on, including AI-powered PERSONA, Mullen's proprietary advanced facial recognition technology. Mullen EVs on tour include: Mullen FIVE EV crossover, Mullen GT high performance electric sports car, Mullen FIVE RS ultra-high performance sport EV crossover, Mullen ONE class 1 commercial EV cargo van, Mullen THREE class 3 commercial low cab forward, and the Bollinger B2 electric pickup. "I'm grateful for the continued support and to be embarking on the second year of the ‘Strikingly Different' tour with many more Mullen vehicles to showcase," said David Michery, CEO and chairman of Mullen Automotive. "With every stop of the tour, we aim to showcase the power, performance and possibilities of our EVs."

To view the full press release, visit https://ibn.fm/GA1PH

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Friday's trading session at $0.6432, off by 18.5823%, on 70,457,493 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6291/$189.99.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Announces Commencement of Stock Buyback Program
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Unveils Ultra-High-Performance FIVE RS Crossover
• Hyundai Sets Sights on Indian EV Market with Five New Models

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

Los Angles Mayor Karen Bass is expected to announce a new official to head the city's marijuana regulatory agency. Bass is changing leadership in a myriad of city agencies and recently listed the position of executive director of Los Angeles' Department of Cannabis Regulation (DCR) on the city employment site. Interested candidates have until 4 p.m. on Aug. 18, 2023,  to submit their applications for the DCR executive director position. With an annual salary of $155,681 to $276,075, the DCR executive director will oversee an agency of 55 employees and a recreational cannabis market that sells roughly $1 billion worth of cannabis products every year, a feat that equals states with older adult-use cannabis markets. The California Department of Tax and Fee Administration states that Los Angeles' recreational marijuana program generated $236,871,994 in taxable revenue during the first quarter of the year. With California being home to what is arguably the largest marijuana market in the world, it's no surprise that the state's most populous city has an adult-use market that rivals established markets in entire states. The surging sales of marijuana have created opportunities for enterprises such as IGC Pharma Inc. (NYSE American: IGC) to start taking cannabis drug products through the clinical development process so that patients can access those medicines through the conventional medical system as products gain FDA approval.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.331, off by 2.6471%, on 92,010 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.74.

Recent News

• IGC Pharma Inc. (NYSE American: IGC) - 420 with CNW - LA Mayor to Announce Head of City Marijuana Agency
• 420 with CNW - Gallup Poll Finds Highest Ever Support for Cannabis Legalization Among Republicans
• 420 with CNW - Cannabis Industry Lobbying Increases as Looming Government Shutdown Leaves SAFE Banking in Balance

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services' (OTCQB: SHRG) wholly owned subsidiary, MyTravelVentures, recently completed its first-ever Venture Trip at the Sensira Resort and Spa in Cancun, Mexico. "According to a report from the U.S. Travel Association, total travel spending in May improved to 1.4% above May 2022 levels and was up 5.5% year-to-date through May 2023. In addition, air travel demand remained above May 2022. Furthermore, Forbes is reporting that, even with continuing inflation, layoffs and a potential recession, ‘2023 travel trends show no slowdown,'" a recent article reads. "This is the ideal climate for MyTravelVentures to prosper and grow. The company's subscription-based membership plan, which is available for a recurring monthly fee with no contracts or commitments, offers members full access to exclusive deals across the travel industry. These deals represent savings of up to 65% on a variety of services, including flights, hotels, transportation and events; the plan even includes nontravel-related services such as retailer discounts, cash-back programs and telehealth services. Even more exciting are the company's curated, all-inclusive group vacation packages. These exclusive Venture Trips offer premium resort getaways with immersive experiences."

To view the full article, visit https://ibn.fm/fefoY

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

• Sharing Services Global Corporation (SHRG) - InvestorNewsBreaks - Sharing Services Global Corporation's (SHRG) MyTravelVentures Poised as '2023 Travel Trends Show No Slowdown'
• InvestorNewsBreaks - Sharing Services Global Corporation (SHRG) Continues Looking for Opportunities to Innovate, Offer 'neXt-Level' Products
• Sharing Services Global Corp. (SHRG) Subsidiary Celebrates Inaugural Venture Trip as Travel Projected to Grow

Prospera Energy Inc. (TSX.V: PEI) (FRA: OF6B) (OTC: GXRFF)

The QualityStocks Daily Newsletter would like to spotlight Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) .

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. The company uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery.

Prospera is primarily focused on optimizing hydrocarbon recovery from legacy fields through environmentally safe and efficient reservoir development methods and production practices. It is in the midst of a three-stage restructuring process aimed at prioritizing cost effective operations while appreciating production capacity and reducing liabilities.

The company is based in Calgary, Alberta, Canada.

Operations

Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8% of total reserves having been recovered via legacy vertical well technology.

Restructuring Initiative

In 2021, Prospera enacted a top-down reorganization. The early results of these efforts were on display in May 2023, when the company reported a three-fold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations.

Prospera noted in the news release that it has positioned itself in 2023 to execute the second phase of its development plan aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan.

During the company’s investor summit in August 2023, Prospera CEO Samuel David provided more information regarding this three-phase strategy:

Phase I

Prospera completed the first phase of its restructuring by optimizing operations at its existing assets and addressing legacy arrears and non-compliance issues.

At the beginning of this transformation, the company was producing just 80 barrels of oil equivalent (BOE) per day. In Q4 of last year, Prospera peaked at nearly 1,200 BOE per day. Its breakeven is around 500 barrels per day, illustrating the opportunity for free cash flow. This prospect has driven Prospera’s capital development and optimization in recent quarters.

After a temporary slowdown in production due to harsh winter conditions, Prospera is currently producing about 800 BOE per day and anticipates an additional 300-500 barrels of daily production following the completion of ongoing site maintenance work.

This sustained increase has pushed the company’s NPV from roughly $3 million prior to the restructuring efforts to approximately $72 million today.

In an effort to build on this progress and maximize its available resources, Prospera piloted two horizontal reentries to assess a potential horizontal well transformation at its properties.

Phase II

Following up on the optimization efforts of Phase I, Prospera aims to commence a horizontal well transformation at its properties in the coming months. Based on its pilot wells from Phase I, the company has proposed 10 horizontal well locations at its Cuthbert and Heart Hills properties.

Prospera has likewise proposed eight medium light oil direction wells at its Alberta property, and it is exploring strategic acquisitions aimed at expanding its core area and diversifying its product mix.

Other facets of Phase II include piloting an enhanced oil recovery (EOR) application and continuing to execute its liability management goals and ESG initiatives. Prospera has already abandoned 60 vertical wells as part of its three-year LMR plan to reclaim surface land and reduce the environmental footprint of its operations.

Phase III

Beginning next year, Phase III of Prospera’s corporate redevelopment strategy will focus on continuing the company’s horizontal modular development to appreciate production and optimize recovery of remaining reserves. Prospera intends to implement full-scale EOR applications based on the results of its Phase II pilot program, which is forecast to optimize recovery by greater than 10%.

Prospera also intends to continue its acquisition strategy to diversify its product mix. Its goal, as detailed by in August 2023 investor summit, is to attain 50% light oil, 40% heavy oil and 10% gas – all while continuing to eliminate carbon emissions as part of its existing ESG initiatives.

Poised for Growth

Following its transformational efforts in 2022, Prospera is poised to achieve record growth in 2023. The company has forecast significant reductions in production costs through 2024, alongside sizable increases in daily production.

Prospera is currently exploring strategic acquisition targets to potentially increase its production beyond 5,000 BPD while expanding its reserve base to a billion barrels.

Market Opportunity

While the oil and gas industry faces long-term geopolitical and macroeconomic uncertainty, there is a clear trend to secure supply in the short term. According to Deloitte, the global upstream industry ended 2022 with some of the highest free cash flows on record, driving reinvestment in hydrocarbons and overall investment in clean energy.

The Energy Information Administration recently forecast a dip in global oil inventories over each of the next five quarters, placing upward pressure on oil prices. The agency further forecasts a YoY increase in fuel consumption, exacerbating the effects of OPEC+ production cuts that are set to remain in place through 2024.

For Prospera, these forecasts are promising. The company aims to build on its recent financial growth in the coming months (Prospera reported a three-fold YoY increase in revenue to $13.9 million in 2022), hitting a projected $57 million in total revenue by the end of 2024 while working to expand its core area holdings through accretive M&A transactions.

Leadership Team

Prospera is led by a team with extensive, diverse petroleum industry experience spanning both reservoir management and operations of oil and gas assets. The team boasts a proven track record of reorganizing companies, structuring financing arrangements and positioning for growth.

Samuel David is the company’s President and CEO. He brings to Prospera over 32 years of experience in operation, development and management of oil and gas assets and companies. Mr. David holds a B.Sc. in Mechanical Engineering and a B.A. in Economics from the University of Calgary. His background consists of both engineering and executive management experience with majors Petro-Canada, AEC Oil & Gas (now EnCana / Cenovus) and Husky Energy, as well as founding and operating juniors Ventura Energy and First West Petroleum. Mr. David has proven expertise in corporate planning, production, reservoir engineering, depletion strategies, EOR, property evaluations, acquisitions and divestitures.

George Magarian is VP Subsurface for Prospera. He is a professional petroleum geologist (APEGA) with over 36 years’ experience in the Western Canada Sedimentary Basin. After graduating with an Honors B.Sc. degree in Earth Science from the University of Waterloo, Mr. Magarian spearheaded many successful exploration programs, conducted evaluations for improved recovery schemes and assessed/exploited unconventional oil reservoir opportunities. He has held roles of increasing responsibility, from exploration geologist at oil industry major Petro-Canada and intermediates Anderson Exploration and Jordan Petroleum, to geoscience manager and VP exploration at junior companies Ionic Energy, Gentry Resources and Westfire Energy.

Chris Ludtke is the company’s VP Finance & Accounting. He is a high functioning finance leader with extensive expertise in finance, budgets and planning, accounting, economic evaluation, management, governance and sound decision making. Mr. Ludtke has 20 years of experience within the oil and gas, clean energy and renewables industries, including 12+ years working for Husky Energy before moving into an executive role in the junior oil and gas and hydrogen space. He graduated from the University of Lethbridge (Bachelor of Management) and is a Chartered Professional Accountant in the Province of Alberta.

Matthew Kenna is the CFO of Prospera. He has over 30 years’ experience leading organizations and helping them expand, drive efficiencies and grow profitability. Mr. Kenna is a professional accountant (CPA, CMA) and spent 15 years heading up the financial and operating departments at KUDU Industries, where he fostered financing arrangements, client relationships and manufacturing teams to take the organization from $35M to $150M in revenue. He has extensive experience turning companies around, growing them and building efficient organizations.

Prospera Energy Inc. (OTC: GXRFF), closed Friday's trading session at $0.09, up 1.1236%, on 49,080 volume. The average volume for the last 3 months is 49,080 and the stock's 52-week low/high is $0.0352/$0.134.

Recent News

• Prospera Energy Inc. (TSX.V: PEI) (FRA: OF6B) (OTC: GXRFF) - Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Is 'One to Watch'
• InvestorNewsBreaks - Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Announces Commencement of Modular Horizontal Infill Well Program
• Prospera Energy Inc. and Aduro Clean Technologies Advance Collaboration on Pilot Project for Partial Upgrading of Bitumen

RJD Green Inc. (OTC: RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (OTC: RJDG) .

RJD Green Inc. (OTC: RJDG) is a holding company focused on managing portfolio assets while actively exploring potential acquisitions and opportunities in diversified industries. The company currently operates in three divisions: RJD Green Healthcare Division, Earthlinc Environmental Solutions and Silex Holdings Inc.

The company’s corporate management team has a history of success in both public and private arenas, with diverse enterprise experience that includes RJD Green’s three current market sectors of focus. Corporate overhead is maintained at minimal operating cost, with each officer and team member maintaining daily management responsibility for specific operating divisions and entities.

Each acquisition and asset is operated as a separate profit center, with the recognition that, in small business operations, proficiency and frugal budgeting are required to maximize profitability. The RJD Green team excels in working collaboratively with the company’s business partners, creating common efforts for reaching mutual reward from its relationships.

The company is headquartered in Tulsa, Oklahoma.

Business Divisions

RJD Green Healthcare Division

Through this division, the company has developed a business model that utilizes the healthcare industry experience and extensive industry relationships of its management team. RJD Green’s leadership has long-term relationships with many key providers within the service sectors of the healthcare industry.

The first RJD Green Healthcare Division services acquisition was IoSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers. The IoSoft team has years of experience and relationships within the more than a million providers in the healthcare market.

Earthlinc Environmental Solutions

This division was formed to promote green applied technologies and offer environmental services in North America. Its focus is on performance-driven solutions for environmental-based issues.

The first acquisition, Animal Waste Management, is a patented technology that is fully developed and entering the market for waste processing on commercial chicken and hog farms. Development was supported by the University of Arkansas and the Missouri Department of Natural Resources.

The acquired technology controls the liquid, solid and gas waste generated, creating an odorless, clean, bacteria-free by-product that can be used for animal feed filler, while allowing the water to be reused as ground water on the farm.

Silex Holdings Inc.

This division was formed for the purpose of acquiring and managing high growth assets and business enterprises. Its operations are focused on acquisitions in specialty industrial contracting, building material products and construction services.

Acquisitions are modeled to offer immediate growth, such as a unique geographical or proprietary market niche or other differentiating quality, and are synergistic in corporate management and administration, as well as sales and marketing.

The company’s first acquisition through this division, Silex Interiors, is a manufacturer, distributor and installer of countertops, cabinets and related kitchen and bath products. Silex is modeled for expansion into major markets nationally through internal expansion, acquisition and franchising.

Market Opportunity

According to a report from Reportlinker.com, the global healthcare services market is expected to grow from $6.8 billion in 2021 to $10.4 billion in 2026 at a CAGR of 8.6%. The report attributed the forecast growth primarily to healthcare companies restructuring their operations as a result of lasting challenges presented by the COVID-19 pandemic.

Research firm Verdantix reported the environmental services market was worth an estimated $35.2 billion in 2022 and is expected to reach a value of $50.6 billion by 2029, marking a CAGR of 6.3% for the forecast period. Verdantix identified factors driving growth to include changing environmental compliance regulations, rising demand for infrastructure projects and increased ESG reporting scrutiny.

In 2021, Icon Market Research estimated the global specialty trade contractors market at $3.9 billion, forecasting that it will reach $5.7 billion by 2028 at an expected CAGR of 9.2% through the identified period.

Management Team

Ron Brewer is CEO of RJD Green. He has served as a corporate officer in both public and private companies, including as president of Mid-Continent Companies. He has experience in all three industries represented by the company’s divisions. He has provided management and guidance to five environmental services and technology companies, as well as guiding business development services in healthcare for hospitals, practice assistance and various service providers in the sector. He has also developed three separate companies in the same construction products sector.

Jerry Niblett is COO at RJD Green. He has over 19 years of management success in oil and gas operations at both corporate and small-cap enterprises. His corporate employment history includes Dominion Energy, Texaco, Shell and Sunoco Pipeline LP. He has worked in multiple energy sectors, including petro-chemical refining, natural gas compression, crude oil pipeline and storage, oil and gas exploration, and oil and gas products and services business development. He holds a bachelor’s degree in Total Quality Management, graduating with honors.

John Rabbitt is CFO at RJD Green. He has worked at Fortune 500 firms including Pillsbury, PepsiCo and CPA firm Ernst and Ernst. He played a key role in the growth of MEI Corp. from $20 million annual revenue to $850 million annually in nine years, at which time it was acquired by PepsiCo. He has a proven track record in both fast-growth and turnaround environments, serving in CEO/COO and CFO positions for firms ranging from $5 million to $300 million annual revenue. His education includes degrees in accounting and business from Drake University and PepsiCo’s Management Institute.

RJD Green Inc. (OTC: RJDG), closed Friday's trading session at $0.0056, even for the day, on 1 volume. The average volume for the last 3 months is 1 and the stock's 52-week low/high is $0.0041/$0.01315.

Recent News

• RJD Green Inc. (OTC: RJDG) - RJD Green Inc. (RJDG) Is 'One to Watch'
• RJD Green, Inc. (RJDG) Timely Filed Q3 Quarterly Report on OTC Markets; Shows Revenue from Operations of $3,652,371 as of May 31, 2023
• RJD Green (OTCPK: RJDG) Announced a Major Commercial Contract Has Been Awarded Silex Holdings Division in the Texas Region

OK Stone Engineering Inc.

The QualityStocks Daily Newsletter would like to spotlight OK Stone Engineering Inc.

OK Stone Engineering Inc. is a Texas-based company formed to manufacture engineered quartz slabs to be used as materials for countertops and tile in the building and construction industry. The company’s manufacturing process uses next-generation technologies which reduce costs, improve the quality of the finished product and increase safety of workers in the manufacturing process.

OK Stone is the first high tech source of U.S.-made quartz stone products. The company, with joint venture partner Breton S.p.A., has announced a new factory for engineered stone in Fort Worth, Texas, to fill the massive supply gap in the U.S. market, where the domestic shortage is projected to increase to 140 million square feet annually by 2026. Construction of the facility is scheduled to begin in 2024, with production projected to start in mid to late 2025 and the is facility projected to be scaling to full production in early 2026.

The factory will be the first in the U.S. to employ Breton’s Bioquartz® technology, a transformative state-of-the-art manufacturing process. There are only nine engineered stone slab manufacturers in the U.S., and seven of those are based on older Breton technology. Only OK Stone is investing in this latest technology while other manufacturing facilities risk falling behind.

Products

OK Stone’s licensed Bioquartz® manufacturing technology, which has been under development for a decade, will provide a significant competitive advantage in the market by solving the most frustrating problems faced by customers. Breton, based in Italy, is the definitive international leader in designing and developing engineered stone production plants, with more than 95% of global market share.

This next-gen manufacturing technology will allow OK Stone to source a more reliable and less expensive supply of domestic raw materials, replacing variable supplies from Asia. It also reduces costs by more than 10% while producing quartz slabs with an unlimited range of aesthetic effects that older manufacturing technologies cannot replicate.

Importantly, the Bioquartz® process eliminates the risk that workers can develop silicosis, an incurable lung disease caused by inhaling crystalline silica particles. Expected new government regulations to prevent silicosis are likely to impact other U.S. manufacturers. The company’s expected regulatory compliance, as well as its avoidance of international shipping costs for raw materials – which have been unstable since 2021 – are among the factors likely to provide OK Stone with major competitive advantages in the market.

The company will sell its factory output through the existing network of stone distributors that supply the building and construction industry.

Market Opportunity

According to a report by Allied Market Research, a research, consulting and advisory firm, the global engineered stone market was valued at $21.1 billion in 2021 and is projected to reach $35.1 billion by 2031, growing at a CAGR of greater than 5% for the forecast period.

Engineered stone is used in a number of applications in the construction industry, including countertops, flooring and wall tiles, fireplaces and more. The report states that rapid expansion in construction is boosting the global demand for engineered stone.

Management Team

OK Stone’s management team recently designed, built and operated a Breton factory with more than $100 million in annual revenues.

The CEO of OK Stone has almost two decades of experience in the engineered stone industry. He began as a production engineer, later hired as a factory manager and eventually in the role of Managing Partner an an Industrial Investment fund, focusing on investments in engineered stone. He holds a Mechanical Engineering degree and an MBA.

The Chief Marketing Officer at OK Stone has more than 15 years of experience as a sales and marketing executive in the industry. He has worked for the top tier of engineered surfaces companies as well as a significant U.S.-based engineered stone company. He has recently been Sales and Marketing Director of a fully scaled Breton equipped factory, and was previously part of the founding team at a separate Breton factory, where he worked extensively in the U.S. market.

Ronald Max is COO at OK Stone. He has more than 35 years of experience in operations and finance. He has been involved in over $4 billion in real estate transactions and has extensive expertise in complicated ownership structures such as sale-leaseback financing, ground lease bifurcations and real estate securities offerings. In addition, he has experience in creating operating budgets, financial management and industrial real estate development for highly scaled enterprises.

Recent News

• OK Stone Engineering Inc. - OK Stone Engineering Inc. Company Profile
• OK Stone Engineering Inc. Company Profile
• OK Stone Engineering Inc. Company Profile